RB1

RB1
Name	RB1
Ensembl	ENSG00000139687
Omim	180200
Chromosomal location	13q14.2

RB1

RB1 is a tumor suppressor gene encoding a pivotal regulator of cell-cycle progression. It was first implicated in heredity through studies of familial ocular tumors and later connected to broader cancer biology. The RB1 protein controls proliferation via interactions with transcription factors, chromatin regulators, and cell-cycle machinery, linking developmental signaling to cell-fate decisions.

Function and Mechanism

The RB1 protein enforces a G1–S cell-cycle checkpoint by binding to and inhibiting members of the E2F transcription factor family, thereby suppressing transcriptional programs required for DNA replication; canonical interactions include E2F1, E2F2, and E2F3. Phosphorylation by cyclin-dependent kinases such as complexes containing Cyclin D1/CDK4 and Cyclin E/CDK2 triggers conformational changes that release E2F factors, integrating inputs from pathways including PI3K/AKT pathway, MAPK/ERK pathway, and growth factor receptors like EGFR. Beyond cell-cycle control, RB1 associates with chromatin modifiers such as HDAC1, SWI/SNF complex, and DNMT1 to promote heterochromatin formation at centromeric and repetitive sequences, cooperating with the histone methyltransferase SUV39H1. RB1 also participates in DNA damage responses through interactions with ATM and ATR signaling cascades and can influence apoptosis through cross-talk with p53-mediated networks and BCL2 family members.

Gene and Protein Structure

The RB1 locus on chromosome 13q14.2 spans multiple exons and produces a ~4.7 kb transcript encoding a ~928–amino-acid protein characterized by an amino-terminal domain, a conserved "pocket" region composed of A and B subdomains, and a C-terminal domain important for regulatory phosphorylation. The pocket domain mediates binding to LXCXE motif-containing proteins such as viral oncoproteins from Human papillomavirus and cellular regulators like E2F4. RB1 harbors numerous CDK phosphorylation sites targeted by CDK4/CDK6 complexes; mutation or deletion of pocket-domain residues disrupts tumor suppressor activity and protein–protein interactions. Germline and somatic allelic events include point mutations, intragenic deletions, large chromosomal deletions often detected by cytogenetics and copy-number assays developed in clinical centers like St Jude Children's Research Hospital and repositories such as The Cancer Genome Atlas.

Role in Cancer and Clinical Significance

Loss of RB1 function underlies hereditary retinoblastoma first described in pedigree analyses by early 20th-century clinicians and subsequently mapped through linkage studies; RB1 inactivation follows Knudson’s two-hit hypothesis established in studies on familial and sporadic tumors. RB1 deficiency contributes to malignancies beyond retinoblastoma, including subsets of small cell lung carcinoma, osteosarcoma, breast cancer, and bladder cancer, often cooperating with alterations in TP53 and amplification of MYC or MDM2. Clinical phenotypes vary with mutation class: null alleles predispose to bilateral retinoblastoma and secondary neoplasms such as soft tissue sarcoma following radiotherapy, while hypomorphic alleles can produce low-penetrance retinoblastoma or later-onset cancers. Loss of heterozygosity at 13q14 is a recurrent event detected by cancer genetics laboratories and informs risk stratification in familial cancer clinics and oncogenetics programs at centers like Memorial Sloan Kettering Cancer Center.

Regulation and Interactions

RB1 activity is regulated by cyclin–CDK phosphorylation, targeted dephosphorylation by phosphatases including PP1, and ubiquitin-mediated degradation pathways involving E3 ligases studied in molecular oncology groups at institutions such as Cold Spring Harbor Laboratory. RB1 forms complexes with transcriptional repressors (E2F6-containing complexes), chromatin remodelers (BRG1 of the SWI/SNF complex), and nuclear scaffold proteins including Lamin A/C. Viral oncoproteins from Adenovirus, Simian virus 40, and Human papillomavirus bind the RB1 pocket, functionally inactivating RB1 to drive cellular transformation. Post-translational modifications beyond phosphorylation—acetylation, methylation, and SUMOylation—modulate RB1 localization and partner selection, as reported by research groups at universities like Harvard University and University of Cambridge.

Model Organisms and Experimental Studies

Mouse models with germline or conditional Rb1 deletions recapitulate aspects of human tumorigenesis and developmental defects and have been developed by laboratories at institutions such as The Jackson Laboratory. Rb1-null mice exhibit embryonic lethality with defects in neurogenesis and erythropoiesis, while tissue-specific knockouts in retina, lung, and bone marrow reveal context-dependent roles in tumor suppression and differentiation. Drosophila studies of the RB1 homolog Rbf illuminated conserved pocket-domain functions and interactions with developmental pathways investigated by groups at Max Planck Institute and Stanford University. Cell-based models using CRISPR–Cas9 and RNAi in lines from repositories such as ATCC have enabled synthetic-lethality screens identifying genetic dependencies that are exploitable therapeutically.

Therapeutic Implications and Diagnostics

RB1 status informs treatment decisions and clinical trial design: tumors lacking functional RB1 are often resistant to CDK4/6 inhibitors like palbociclib, which require an intact RB1 pathway for efficacy, while those with RB1 loss may be sensitive to DNA-damage–based regimens or agents targeting compensatory vulnerabilities such as mitotic kinases (e.g., Aurora kinase inhibitors). Diagnostic assays include sequencing panels used at clinical laboratories associated with National Cancer Institute programs, fluorescence in situ hybridization employed in pathology departments at hospitals like Mayo Clinic, and immunohistochemistry for RB1 protein performed in oncologic pathology services. Genetic counseling for families with germline RB1 mutations is provided by clinical genetics centers at institutions including Great Ormond Street Hospital and informs surveillance protocols, early detection strategies, and risk-reduction counseling.

Category:Tumor suppressor genes